Exposure to air pollution is associated with an increased risk for neurological disorders in older adults.
In this post hoc analysis, the effect of pimavanserin on anxious depression was determined from CLARITY, a randomized, double-blind, placebo-controlled study in patients with major depression and an inadequate response to previous therapy.
This retrospective and prospective diagnostic study evaluated autopsy and biopsy skin samples from neuropathologically and clinically diagnosed patients with Parkinson Disease and controls without PD.
To identify markers of resistance to developing Parkinson disease among LRRK2 mutation carriers, metabolomic profiling in individuals with Parkinson disease and unaffected controls, were carried out with and without the LRRK2 mutation.
After transplanting hESC-derived midbrain dopamine (mDA) into the striatum of a PD model mouse, researchers found extensive graft integration with host circuitry.
Subthreshold depression was found to be a problem with Parkinson Disease patients. Quality of life is worse and non-motor symptoms burden is greater.
Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Reduced circadian rhythmicity is associated with an increased risk for incident Parkinson disease.
Researchers sought to determine the relationship between neuroimaging markers and other clinical characteristics with mild parkinsonian signs in older adults.
Precision medicine offers a promising therapeutic strategy for patients with Parkinson disease, allowing for tailored treatments which reflect the unique pathophysiology in each patient.